Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients

BACKGROUND: To explore the optimum induction therapy for patients with newly diagnosed multiple myeloma (NDMM) who are eligible but have not yet received autologous stem cell transplantation (ASCT) in China. METHODS: A total of 140 NDMM patients with cytogenetic background were selected from the Cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liang, Yi, Ke, Lan, Hongyan, Zhang, Yajun, Jin, Simin, Mou, Xiaoyu, Xian, Hongming, Fu, Weijun, Li, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279781/
https://www.ncbi.nlm.nih.gov/pubmed/35845500
http://dx.doi.org/10.21037/atm-22-394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279781/
https://www.ncbi.nlm.nih.gov/pubmed/35845500
http://dx.doi.org/10.21037/atm-22-394

Ejemplares similares